本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

CytoMed Therapeutics Limited

1.86
-0.2500-11.85%
成交量:140.19万
成交额:347.04万
市值:2,182.47万
市盈率:-7.44
高:3.10
开:2.52
低:1.68
收:2.11
52周最高:4.05
52周最低:1.65
股本:1,173.37万
流通股本:598.81万
量比:121.61
换手率:23.41%
股息:- -
股息率:- -
每股收益(TTM):-0.2499
每股收益(LYR):-0.1598
净资产收益率:-42.33%
总资产收益率:-22.85%
市净率:3.98
市盈率(LYR):-11.64

数据加载中...

2025/09/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/06/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/06/20

SEC问询函

Form CORRESP - Correspondence
2025/04/28

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/06

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/23

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/04/22

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/05/19

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/05/01

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/24

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/04/21

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/03/31

SEC问询函

Form CORRESP - Correspondence
2023/03/31

SEC问询函

Form CORRESP - Correspondence
2023/03/31

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses